ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boehringer Ingelheim, AstraZeneca and Bristol-Myers Squibb side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Boehringer Ingelheim×AstraZeneca×Bristol-Myers Squibb×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Boehringer IngelheimAstraZenecaBristol-Myers Squibb
studies on the registry2,3054,1972,184
open to participants now61298155
phase 3 studies under way2820082
reach primary completion within a year4516867
programswith a study of their own in two years45+21 named only119+5 named only57+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBoehringer IngelheimAstraZenecaBristol-Myers Squibb
Phase 1

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%
Phase 2

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%
Phase 3

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%
Approved, new studies

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 51 in all. A program counts in each condition its studies name most.

ConditionBoehringer IngelheimAstraZenecaBristol-Myers Squibb
Carcinoma, Non-Small-Cell Lungall three · compare here

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Boehringer Ingelheim in Breast Neoplasms: 2 programs

  1. zongertinibphase 3
  2. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Boehringer Ingelheim in Neoplasms: 1 program

  1. ezabenlimabphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

Boehringer Ingelheim in Small Cell Lung Carcinoma: 5 programs

  1. obrixtamigphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2
  5. Zocilurtatug Pelitecanphase 2

Their studies: Boehringer Ingelheim’s studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Hepatocellularall three · compare here

Boehringer Ingelheim in Carcinoma, Hepatocellular: 1 program

  1. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Hepatocellular in search

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Boehringer Ingelheim in Pulmonary Disease, Chronic Obstructive: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

Heart Failureall three · compare here

Boehringer Ingelheim in Heart Failure: 2 programs

  1. vicadrostatphase 3
  2. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Heart Failure in search

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Bristol-Myers Squibb in Heart Failure: 1 program

  1. delocamtenphase 2

Their studies: Bristol-Myers Squibb’s studies of Heart Failure in search

Colorectal Neoplasmsall three · compare here

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

Boehringer Ingelheim in Lupus Erythematosus, Systemic: 1 program

  1. BI 3000202phase 2

Their studies: Boehringer Ingelheim’s studies of Lupus Erythematosus, Systemic in search

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Obesityall three · compare here

Boehringer Ingelheim in Obesity: 2 programs

  1. survodutidephase 3
  2. BI 3034701phase 2

Their studies: Boehringer Ingelheim’s studies of Obesity in search

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

Idiopathic Pulmonary Fibrosisall three · compare here

Boehringer Ingelheim in Idiopathic Pulmonary Fibrosis: 4 programs

  1. nerandomilastphase 3
  2. BI 3810477phase 2
  3. BI 765423phase 2
  4. BI 1819479phase 2

Their studies: Boehringer Ingelheim’s studies of Idiopathic Pulmonary Fibrosis in search

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Bristol-Myers Squibb in Idiopathic Pulmonary Fibrosis: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Idiopathic Pulmonary Fibrosis in search

Melanomaall three · compare here

Boehringer Ingelheim in Melanoma: 1 program

  1. BI 3810944phase 1

Their studies: Boehringer Ingelheim’s studies of Melanoma in search

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

Neoplasm Metastasisall three · compare here

Boehringer Ingelheim in Neoplasm Metastasis: 1 program

  1. zongertinibphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Liver Cirrhosisall three · compare here

Boehringer Ingelheim in Liver Cirrhosis: 2 programs

  1. survodutidephase 3
  2. BI 3802876phase 2

Their studies: Boehringer Ingelheim’s studies of Liver Cirrhosis in search

AstraZeneca in Liver Cirrhosis: 2 programs

  1. zibotentanphase 3
  2. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Cirrhosis in search

Bristol-Myers Squibb in Liver Cirrhosis: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Liver Cirrhosis in search

Scleroderma, Systemicall three · compare here

Boehringer Ingelheim in Scleroderma, Systemic: 1 program

  1. nerandomilastphase 3

Their studies: Boehringer Ingelheim’s studies of Scleroderma, Systemic in search

AstraZeneca in Scleroderma, Systemic: 2 programs

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3
  2. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Scleroderma, Systemic in search

Bristol-Myers Squibb in Scleroderma, Systemic: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Scleroderma, Systemic in search

Liver Diseasesall three · compare here

Boehringer Ingelheim in Liver Diseases: 2 programs

  1. zongertinibphase 3
  2. vicadrostatphase 3

Their studies: Boehringer Ingelheim’s studies of Liver Diseases in search

AstraZeneca in Liver Diseases: 1 program

  1. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Diseases in search

Bristol-Myers Squibb in Liver Diseases: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Liver Diseases in search

Lung Neoplasmsall three · compare here

Boehringer Ingelheim in Lung Neoplasms: 2 programs

  1. zongertinibphase 3
  2. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Lung Neoplasms in search

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Bristol-Myers Squibb in Lung Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Lung Neoplasms in search

Lymphoma, Large B-Cell, Diffuseall three · compare here

Boehringer Ingelheim in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Lymphoma, Large B-Cell, Diffuse in search

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Bristol-Myers Squibb in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Large B-Cell, Diffuse in search

Colitis, Ulcerativeall three · compare here

Boehringer Ingelheim in Colitis, Ulcerative: 1 program

  1. BI 3032950phase 2

Their studies: Boehringer Ingelheim’s studies of Colitis, Ulcerative in search

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Bristol-Myers Squibb in Colitis, Ulcerative: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colitis, Ulcerative in search

COVID-19all three · compare here

Boehringer Ingelheim in COVID-19: 1 program

  1. apecotrepphase 3

Their studies: Boehringer Ingelheim’s studies of COVID-19 in search

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Bristol-Myers Squibb in COVID-19: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of COVID-19 in search

Prostatic Neoplasms2 of 3 · compare here–

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Renal Insufficiency, Chronic2 of 3 · compare here

Boehringer Ingelheim in Renal Insufficiency, Chronic: 3 programs

  1. vicadrostatphase 3
  2. apecotrepphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Renal Insufficiency, Chronic in search

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

–
Multiple Myeloma2 of 3 · compare here–

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Renal Insufficiency2 of 3 · compare here

Boehringer Ingelheim in Renal Insufficiency: 1 program

  1. survodutidephase 3

Their studies: Boehringer Ingelheim’s studies of Renal Insufficiency in search

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

–
Stomach Neoplasms2 of 3 · compare here–

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

Diabetes Mellitus, Type 22 of 3 · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

–
Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here–

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Lymphoma, Follicular2 of 3 · compare here–

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Bristol-Myers Squibb in Lymphoma, Follicular: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Follicular in search

Carcinoma, Renal Cell2 of 3 · compare here–

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

Bristol-Myers Squibb in Carcinoma, Renal Cell: 3 programs

  1. BMS-986527phase 1
  2. Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506phase 1
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Renal Cell in search

Arthritis, Rheumatoid2 of 3 · compare here–

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

Endometrial Neoplasms2 of 3 · compare here

Boehringer Ingelheim in Endometrial Neoplasms: 1 program

  1. BI 3820768phase 1

Their studies: Boehringer Ingelheim’s studies of Endometrial Neoplasms in search

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Boehringer Ingelheim in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. ezabenlimabphase 3
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2

Their studies: Boehringer Ingelheim’s studies of Squamous Cell Carcinoma of Head and Neck in search

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

–
Triple Negative Breast Neoplasms2 of 3 · compare here–

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Bristol-Myers Squibb in Triple Negative Breast Neoplasms: 1 program

  1. izalontamab brengitecanphase 3

Their studies: Bristol-Myers Squibb’s studies of Triple Negative Breast Neoplasms in search

Kidney Failure, Chronic2 of 3 · compare here–

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Bristol-Myers Squibb in Kidney Failure, Chronic: 3 programs

  1. golcadomidephase 3
  2. admilparantphase 3
  3. mezigdomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Kidney Failure, Chronic in search

Lymphoma2 of 3 · compare here–

AstraZeneca in Lymphoma: 1 program

  1. PRMT5 Inhibitor AZD3470phase 2

Their studies: AstraZeneca’s studies of Lymphoma in search

Bristol-Myers Squibb in Lymphoma: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. repotrectinibphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma in search

Lymphoma, B-Cell2 of 3 · compare here–

Bristol-Myers Squibb in Lymphoma, B-Cell: 1 program

  1. golcadomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, B-Cell in search

Hepatic Insufficiency2 of 3 · compare here

Boehringer Ingelheim in Hepatic Insufficiency: 1 program

  1. BI 1584862phase 2

Their studies: Boehringer Ingelheim’s studies of Hepatic Insufficiency in search

AstraZeneca in Hepatic Insufficiency: 2 programs

  1. atirmociclibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Hepatic Insufficiency in search

–
Lupus Nephritis2 of 3 · compare here–

AstraZeneca in Lupus Nephritis: 1 program

  1. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Lupus Nephritis in search

Bristol-Myers Squibb in Lupus Nephritis: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. BMS-986553phase 1

Their studies: Bristol-Myers Squibb’s studies of Lupus Nephritis in search

Multiple Sclerosis2 of 3 · compare here–

Bristol-Myers Squibb in Multiple Sclerosis: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Multiple Sclerosis in search

Ovarian Neoplasms2 of 3 · compare here

Boehringer Ingelheim in Ovarian Neoplasms: 1 program

  1. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Ovarian Neoplasms in search

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

–
Pancreatic Neoplasms2 of 3 · compare here–

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Bristol-Myers Squibb in Pancreatic Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Pancreatic Neoplasms in search

Bronchiectasis2 of 3 · compare here

Boehringer Ingelheim in Bronchiectasis: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Bronchiectasis in search

AstraZeneca in Bronchiectasis: 1 program

  1. AZD0292phase 2

Their studies: AstraZeneca’s studies of Bronchiectasis in search

–
Crohn Disease2 of 3 · compare here–

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

Bristol-Myers Squibb in Crohn Disease: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Crohn Disease in search

Depressive Disorder, Major2 of 3 · compare here

Boehringer Ingelheim in Depressive Disorder, Major: 1 program

  1. Pramipexoleapproved, new study

Their studies: Boehringer Ingelheim’s studies of Depressive Disorder, Major in search

–

Bristol-Myers Squibb in Depressive Disorder, Major: 1 program

  1. BMS-986511phase 2

Their studies: Bristol-Myers Squibb’s studies of Depressive Disorder, Major in search

Diabetes Mellitus, Type 12 of 3 · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 1 in search

AstraZeneca in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 1 in search

–
Diabetic Nephropathies2 of 3 · compare here

Boehringer Ingelheim in Diabetic Nephropathies: 1 program

  1. vicadrostatphase 3

Their studies: Boehringer Ingelheim’s studies of Diabetic Nephropathies in search

AstraZeneca in Diabetic Nephropathies: 1 program

  1. tozorakimabphase 3

Their studies: AstraZeneca’s studies of Diabetic Nephropathies in search

–
Ischemic Stroke2 of 3 · compare here

Boehringer Ingelheim in Ischemic Stroke: 1 program

  1. Tenecteplaseapproved, new study

Their studies: Boehringer Ingelheim’s studies of Ischemic Stroke in search

–

Bristol-Myers Squibb in Ischemic Stroke: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Ischemic Stroke in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here–

AstraZeneca in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. Menin Inhibitor AZD3632phase 2

Their studies: AstraZeneca’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Bristol-Myers Squibb in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Stroke2 of 3 · compare here

Boehringer Ingelheim in Stroke: 1 program

  1. Tenecteplaseapproved, new study

Their studies: Boehringer Ingelheim’s studies of Stroke in search

–

Bristol-Myers Squibb in Stroke: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Stroke in search

Thrombosis2 of 3 · compare here–

AstraZeneca in Thrombosis: 1 program

  1. andexanet alfaapproved, new study

Their studies: AstraZeneca’s studies of Thrombosis in search

Bristol-Myers Squibb in Thrombosis: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Thrombosis in search

Uterine Cervical Neoplasms2 of 3 · compare here–

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

Bristol-Myers Squibb in Uterine Cervical Neoplasms: 1 program

  1. imzokitugphase 2

Their studies: Bristol-Myers Squibb’s studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Boehringer Ingelheim 24 of 45 · AstraZeneca 68 of 119 · Bristol-Myers Squibb 32 of 57 programs (53 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21, AstraZeneca: 5, Bristol-Myers Squibb: 9).